Exane BNP Paribas analyst Thomas Poutrieux upgraded Bill to Outperform from Neutral with a $90 price target. The company is investing in suppliers’ go-to-market, which will generate sustainable take-rate expansion, the analyst tells investors in a research note. The firm thinks this can lead to 23% annual revenue growth through fiscal 2028. Bill’s valuation “looks cheap” at current levels, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BILL: